Significant Positive Shift in the Cell and Gene Therapies in Rare Disorders Market with 35.8% CAGR During the Study Period (2019-2032) Expected by Analysts at DelveInsight

News provided by

May 09, 2023, 11:00 ET

The dynamics of the cell and gene therapies market in rare disorders are anticipated to change as companies across the globe are thoroughly working toward developing new therapeutic options to treat a wide array of indications.

LAS VEGAS, May 9, 2023 /PRNewswire/ -- DelveInsight's Cell and Gene Therapies in Rare Disorders Market Insights report includes a comprehensive understanding of current treatment practices, emerging cell and gene therapies for various rare disorders, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Takeaways from the Cell and Gene Therapies in Rare Disorders Market Report

As per DelveInsight analysis, the cell and gene therapies in rare disorders market size in the 7MM was approximately USD 1.5 billion in 2022.
According to the assessment done by DelveInsight, the estimated total prevalent cases of selected indications for cell and gene therapies in rare disorders in the 7MM were approximately 900K in 2022.
Leading companies developing novel cell and gene therapies for various rare disorders, such as Hemophilia A, Hemophilia B, Fabry disease, Retinitis Pigmentosa, Amyotrophic Lateral Sclerosis, Duchenne Muscular Dystrophy, and others include Roche, Freeline Therapeutics, Spark Therapeutics, Astellas Gene Therapies, Actus Therapeutics, GenSight Biologics, Coave Therapeutics, Johnson & Johnson, MeiraGTx, Applied Genetic Technologies Corporation, GenSight Biologics, Nanoscope Therapeutics, 4D Molecular Therapeutics, Ocugen, jCyte, ReNeuron, REGENXBIO, Amicus Therapeutics, Pfizer, Sarepta Therapeutics, Capricor Therapeutics, Nippon Shinyaku, Brainstorm Cell Therapeutics, CRISPR Therapeutics, Vertex Pharmaceuticals, Editas Medicine, Sangamo Therapeutics, Krystal Biotech, Abeona Therapeutics, Castle Creek Biosciences, Holostem Terapie Avanzate S.r.l., RHEACELL, Ishin Pharma, Anterogen, Ultragenyx Pharmaceutical, and others.
The promising cell and gene therapies for various rare disorders in the pipeline include Giroctocogene fitelparvovec, Dirloctocogene samoparvovec, Fidanacogene elaparvovec, Verbrinacogene setparvovec (FLT-180a), FLT190, Isaralgagene civaparvovec (ST-920), 4D-310, SPK-3006, AT845, ACTUS-101, LUMEVOQ (lenadogene nolparvovec), CTx-PDE6b, Botaretigene sparoparvovec, ATGC-501 (laruparetigene zosaparvovec), GS030, MCO-010 (sonpiretigene isteparvovec), 4D-125, OCU400, jCell, RGX-121, AT-GTX-502 (scAAV9.P546.CLN3), PF-06939926, SRP-9001, CAP-1002, NurOwn (MSC-NTF cells), Exagamglogene autotemcel, EDIT-301, BIVV003, VYJUVEK (beremagene geperpavec), EB-101, D-Fi (dabocemagene autoficel), RV-LAMB3-transduced epidermal stem cells, Allogeneic ABCB5-positive Stem Cells, ISN001, ALLO-ASC-SHEET, DTX301, UX111 (ABO-102), DTX401 (AAV8G6PC), and others.
In July 2022, the Institute for Clinical and Economic Review (ICER) released a final evidence report assessing the comparative clinical effectiveness and value of ZYNTEGLO (betibeglogene autotemcel) for treating beta-thalassemia.
In May 2022, Orchard Therapeutics reached an agreement with Gesetzliche Krankenversicherung Spitzenverband (GKV-SV), which will result in reimbursed access to LIBMELDY (atidarsagene autotemcel) for all metachromatic leukodystrophy (MLD) patients in Germany who fall within the scope of the European marketing authorization.

Discover which therapies are expected to grab the major cell and gene therapies in rare disorders market share @ Cell and Gene Therapies in Rare Disorders Market Report

Cell and Gene Therapies in Rare Disorders Overview

Cell and gene therapies use genes and cells to treat disease. A gene is a unit of DNA containing genetic information passed down from generation to generation. The genome comprises all genes; genes may contain information on observable features such as height or eye color. Many genes contain instructions for RNA or protein molecules that are not visible from the outside but serve crucial tasks in the body's cells. Cells are the building blocks of plants and animals (including humans); they are small functional units that work together to generate organs and tissues. Cell and gene therapy technology is quickly evolving for many different diseases. However, cell and gene treatments are still experimental drugs, and much more study is required before many of these therapies are available to patients worldwide.

Cell and Gene Therapies in Rare Disorders Epidemiology Segmentation

DelveInsight estimates that there were approximately 900K prevalent cases of selected indications for cell and gene therapies in rare disorders in the 7MM in 2022.

As per our analysis, the highest prevalent cases from the selected indications for cell and gene therapies in rare disorders were for Retinitis Pigmentosa in the United States, whereas the least cases were reported for Hunter Syndrome in 2022.

The cell and gene therapies in rare disorders market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalent Cases of Shortlisted Indications for Cell and Gene Therapies in Rare Disorders
Total Indication Eligible-wise Cases for Cell and Gene Therapies in Rare Disorders
Indication-wise Treated Cases of Cell and Gene Therapies

Cell and Gene Therapies in Rare Disorders Market Insights

Numerous cell and gene therapies for rare diseases are currently approved in the 7MM, including retinitis pigmentosa (LUXTURNA), beta-thalassemia (ZYNTEGLO), epidermolysis bullosa (JACE), limbal stem cell deficiency (OCURAL), and many others. As per Delveinsight analysis, the total cell and gene therapies in rare disorders market size was around USD 1.5 billion in 2022. According to predictions, the United States will have the largest cell and gene therapies in rare disorders market. ZOLGENSMA produced the highest revenue of roughly USD 1 billion among the 7MM in 2022, while ROCTAVIAN is predicted to take the highest market share by 2032. ROCTAVIAN has received conditional approval in Europe for the treatment of severe hemophilia A. In addition to this approval, BioMarin Pharmaceutical is working to approve the drug in the United States, with a PDUFA target action date of June 30, 2023.

Hemophilia A is predicted to produce the most revenue among the selected indications by 2032, owing to the precedence of existing high treatment cost and expected high cost for emerging therapies along with significant residual unmet need. Gene treatments for Hemophilia A are estimated to earn around USD 6 billion in sales revenue by 2032 in the 7MM. The field of cell and gene therapies for rare indications is expected to rapidly expand in the coming years, as an increasing number of companies submit investigational new drug applications for these treatments each year, along with rising regulatory approval in the United States and Europe. In terms of manufacturing aspects of cell and gene therapies, there will be more competition for contract manufacturing businesses and pharmaceutical/biotechnology firms. The competition for contract manufacturing organization's production capacity will intensify as more companies enter the cell and gene therapy market, possibly driving up manufacturing costs. To ensure pharmaceutical/biotechnology firms can compete or obtain an advantage over competitors, companies may need to invest in manufacturing technologies or acquire companies with manufacturing expertise.

To know more about cell and gene therapies in rare disorders treatment guidelines, visit @ Cell and Gene Therapy Insights

Emerging Cell and Gene Therapies for Hemophilia A and Key Companies

Giroctocogene fitelparvovec: Pfizer/Sangamo Therapeutics
Dirloctocogene samoparvovec: Roche

Emerging Cell and Gene Therapies for Hemophilia B and Key Companies

Fidanacogene elaparvovec: Pfizer/Spark Therapeutics
Verbrinacogene setparvovec (FLT-180a): Freeline Therapeutics

Emerging Cell and Gene Therapies for Fabry Disease and Key Companies

FLT190: Freeline Therapeutics
Isaralgagene civaparvovec (ST-920): Sangamo Therapeutics
4D-310: 4D Molecular Therapeutics

Emerging Cell and Gene Therapies for Pompe Disease and Key Companies

SPK-3006: Spark Therapeutics
AT845: Astellas Gene Therapies
ACTUS-101: Actus Therapeutics

Emerging Cell and Gene Therapies for Leber Hereditary Optic Neuropathy and Key Companies

LUMEVOQ (lenadogene nolparvovec): GenSight Biologics

Emerging Cell and Gene Therapies for Retinitis Pigmentosa and Key Companies

CTx-PDE6b: Coave Therapeutics
Botaretigene sparoparvovec: Johnson & Johnson/ MeiraGTx
ATGC-501 (laruparetigene zosaparvovec): Applied Genetic Technologies Corporation
GS030: GenSight Biologics
MCO-010 (sonpiretigene isteparvovec): Nanoscope Therapeutics
4D-125: 4D Molecular Therapeutics
OCU400: Ocugen
jCell: jCyte

Emerging Cell and Gene Therapies for Hunter Syndrome and Key Companies

RGX-121: REGENXBIO

Emerging Cell and Gene Therapies for Batten Disease and Key Companies

AT-GTX-502 (scAAV9.P546.CLN3): Amicus Therapeutics

Emerging Cell and Gene Therapies for Duchenne Muscular Dystrophy (DMD) and Key Companies

PF-06939926: Pfizer
SRP-9001: Sarepta Therapeutics
CAP-1002: Capricor Therapeutics/Nippon Shinyaku

Emerging Cell and Gene Therapies for Amyotrophic Lateral Sclerosis (ALS) and Key Companies

NurOwn (MSC-NTF cells): Brainstorm Cell Therapeutics

Emerging Cell and Gene Therapies for Beta Thalassemia and Sickle Cell Anemia and Key Companies

Exagamglogene autotemcel: CRISPR Therapeutics/Vertex Pharmaceuticals
EDIT-301: Editas Medicine
BIVV003: Sangamo Therapeutics

Emerging Cell and Gene Therapies for Dystrophic Epidermolysis Bullosa and Key Companies

VYJUVEK (beremagene geperpavec): Krystal Biotech
EB-101: Abeona Therapeutics
D-Fi (dabocemagene autoficel): Castle Creek Biosciences
RV-LAMB3-transduced epidermal stem cells: Holostem Terapie Avanzate S.r.l.
Allogeneic ABCB5-positive Stem Cells: RHEACELL
ISN001: Ishin Pharma
ALLO-ASC-SHEET: Anterogen

Emerging Cell and Gene Therapies for Ornithine Transcarbamylase Deficiency and Key Companies

DTX301: Ultragenyx Pharmaceutical

Emerging Cell and Gene Therapies for Sanfilippo Syndrome Type A and Key Companies

UX111 (ABO-102): Ultragenyx Pharmaceutical

Emerging Cell and Gene Therapies for Glycogen Storage Disease Type IA and Key Companies

DTX401 (AAV8G6PC): Ultragenyx Pharmaceutical

Learn more about the FDA-approved cell and gene therapies for rare disorders @ Approved Cell and Gene Therapies in Rare Disorders Treatment

Cell and Gene Therapies in Rare Disorders Market Dynamics

The cell and gene therapies in rare disorders market is predicted to grow positively due to an increase in the approval of a growing number of gene therapies and their ease of adoption following approval, the ability to treat a wide range of conditions, an increase in the number of cases, an expected one-time dosing approach, and curative treatment options.

The approval of LIBMELDY, SKYSONA, HOLOCLAR, UPSTAZA, ROCTAVIAN, and other medicines has successfully created regulatory channels for the development of further cell and gene therapies. Companies around the world are working hard to develop new cell and gene therapies options to treat a wide range of indications, such as hemophilia A and B, lysosomal storage disorder (Fabry, Pompe Disease, Danon Disease, MPS I, MPS II, MPS III), neurological disorders (Batten, Parkinson), musculoskeletal disorders (DMD, myotubular myopathy), eye diseases (achromatopsia, limbal stem cell deficiency, retinitis pigmentosa, retinoschisis, age-related macular degeneration, Leber's hereditary optic neuropathy), and other indications such as diabetic macular edema, inborn metabolism disorder (Wilson's disease, Phenylketonuria, OTC deficiency/urea cycle disorders), dystrophic epidermolysis bullosa, gangliosidosis, and xerostomia.

Many diseases' treatment landscapes have drastically evolved in the last few years. Companies are now developing cell and gene therapies that will play an important role in the future, particularly in the treatment of rare genetic disorders. The process of defining ideal candidates for given gene therapy and cell therapy will have to wait for the enrolment and long-term follow-up of a sufficient number of study subjects to provide satisfactory clarity regarding its safety and efficacy. In conclusion, the future of cell and gene therapy looks optimistic. Several clinical trials have yielded favorable results in terms of safety and efficacy. The findings of these studies motivate additional research into many indications, and the current scenario predicts a positive shift in the cell and gene therapies in rare disorders market for the forecast period.

However, several factors may impede the growth of cell and gene therapies in rare disorders market in the coming years. Despite advances since the enactment of the Orphan Drug Act, people in the United States with rare diseases continue to face challenges to diagnosis, care, and treatment. Moreover, in Europe, a possible crisis with gene treatments for rare diseases is developing, and few companies have withdrawn the drug after failing to get reimbursement in the EU.

Report Metrics	Details
Study Period	2019–2032
Coverage	7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Base Year	2019
Cell and Gene Therapies in Rare Disorders Market CAGR	35.8 %
Cell and Gene Therapies in Rare Disorders Market Size in 2022	USD 1.5 Billion
Key Cell and Gene Therapies in Rare Disorders Companies	Roche, Freeline Therapeutics, Spark Therapeutics, Astellas Gene Therapies, Actus Therapeutics, GenSight Biologics, Coave Therapeutics, Johnson & Johnson, MeiraGTx, Applied Genetic Technologies Corporation, GenSight Biologics, Nanoscope Therapeutics, 4D Molecular Therapeutics, Ocugen, jCyte, ReNeuron, REGENXBIO, Amicus Therapeutics, Pfizer, Sarepta Therapeutics, Capricor Therapeutics, Nippon Shinyaku, Brainstorm Cell Therapeutics, CRISPR Therapeutics, Vertex Pharmaceuticals, Editas Medicine, Sangamo Therapeutics, Krystal Biotech, Abeona Therapeutics, Castle Creek Biosciences, Holostem Terapie Avanzate S.r.l., RHEACELL, Ishin Pharma, Anterogen, Ultragenyx Pharmaceutical, and others
Key Pipeline Cell and Gene Therapies in Rare Disorders Therapies	Giroctocogene fitelparvovec, Dirloctocogene samoparvovec, Fidanacogene elaparvovec, Verbrinacogene setparvovec (FLT-180a), FLT190, Isaralgagene civaparvovec (ST-920), 4D-310, SPK-3006, AT845, ACTUS-101, LUMEVOQ (lenadogene nolparvovec), CTx-PDE6b, Botaretigene sparoparvovec, ATGC-501 (laruparetigene zosaparvovec), GS030, MCO-010 (sonpiretigene isteparvovec), 4D-125, OCU400, jCell, RGX-121, AT-GTX-502 (scAAV9.P546.CLN3), PF-06939926, SRP-9001, CAP-1002, NurOwn (MSC-NTF cells), Exagamglogene autotemcel, EDIT-301, BIVV003, VYJUVEK (beremagene geperpavec), EB-101, D-Fi (dabocemagene autoficel), RV-LAMB3-transduced epidermal stem cells, Allogeneic ABCB5-positive Stem Cells, ISN001, ALLO-ASC-SHEET, DTX301, UX111 (ABO-102), DTX401 (AAV8G6PC), and others

Scope of the Cell and Gene Therapies in Rare Disorders Market Report

Therapeutic Assessment: Cell and Gene Therapies in Rare Disorders current marketed and emerging therapies
Cell and Gene Therapies in Rare Disorders Market Dynamics: Conjoint Analysis of Emerging Cell and Gene Therapies in Rare Disorders Drugs
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL's Views, Analyst's Views, Cell and Gene Therapies in Rare Disorders Market Access and Reimbursement

Discover more about cell and gene therapies for rare disorders in development @ Cell and Gene Therapy Clinical Trials

Table of Contents

1	Cell and Gene Therapies in Rare Disorders Market Key Insights
2	Cell and Gene Therapies in Rare Disorders Market Report Introduction
3	Cell and Gene Therapies in Rare Disorders Market Key Highlights from Report
4	Executive Summary of Cell and Gene Therapies in Rare Disorders
5	Key Events: Cell and Gene Therapies in Rare Disorders
6	Cell and Gene Therapies in Rare Disorders Epidemiology and Market Forecast Methodology
7	Cell and Gene Therapies in Rare Disorders Market Overview at a Glance in the 7MM
8	Disease Background and Overview of Cell and Gene Therapies in Rare Disorders
9	Epidemiology and Patient Population
10	Marketed Cell and Gene Therapies in Rare Disorders
10.1	Key Competitors in Cell and Gene Therapies in Rare Disorders
10.2	Hemophilia A
10.2.1	ROCTAVIAN (valoctocogene roxaparvovec): BioMarin Pharmaceutical
10.3	Hemophilia B
10.3.1	HEMGENIX (etranacogene dezaparvovec): CSL Behring/uniQure
10.4	Retinitis Pigmentosa
10.4.1	LUXTURNA: Sparks Therapeutics (a company of Roche)/ Novartis
10.5	Spinal Muscular Atrophy (SMA)
10.5.1	ZOLGENSMA (onasemnogene abeparvovec-xioi): Novartis (AveXis)
10.6	Metachromatic Leukodystrophy (MLD)
10.6.1	LIBMELDY (atidarsagene autotemcel): Orchard Therapeutics
10.7	Limbal Stem Cell Deficiency
10.7.1	HOLOCLAR (Autologous human corneal epithelial cells containing stem cells): Holostem Terapie Avanzate S.r.l.
10.7.2	OCURAL: Japan Tissue Engineering
10.7.3	SAKRACY: Hirosaki Lifescience Innovation
10.7.4	NEPIC (EYE-01M): Japan Tissue Engineering
10.8	Adrenoleukodystrophy (ALD)
10.8.1	SKYSONA (elivaldogene autotemcel): bluebird bio
10.9	Beta Thalassemia
10.9.1	ZYNTEGLO (betibeglogene autotemcel): bluebird bio
10.1	Aromatic l-amino acid decarboxylase (AADC) deficiency
10.10.1	UPSTAZA (Eladocagene exuparvovec): PTC Therapeutics
10.11	Dystrophic Epidermolysis Bullosa
10.11.1	JACE (human epidermal cell sheet): Japan Tissue Engineering
10.12	Severe Combined Immunodeficiency due to Adenosine Deaminase Deficiency (ADA-SCID)
10.12.1	STRIMVELIS: Orchard Therapeutics
11	Emerging Drugs
11.1	Key Competitors
11.2	Hemophilia A
11.2.1	Giroctocogene fitelparvovec: Pfizer/Sangamo Therapeutics
11.2.2	Dirloctocogene samoparvovec: Roche (Spark Therapeutics)
11.3	Hemophilia B
11.3.1	Fidanacogene elaparvovec: Pfizer/Spark Therapeutics
11.3.2	Verbrinacogene setparvovec (FLT-180a): Freeline Therapeutics
11.4	Fabry Disease
11.4.1	FLT190: Freeline Therapeutics
11.4.2	Isaralgagene civaparvovec (ST-920): Sangamo Therapeutics
11.4.3	4D-310: 4D Molecular Therapeutics
11.5	Pompe Disease
11.5.1	SPK-3006: Spark Therapeutics (acquired by Roche)
11.5.2	AT845: Astellas Gene Therapies
11.5.3	ACTUS-101: Actus Therapeutics (Acquired by Bayer)
11.6	Leber Hereditary Optic Neuropathy
11.6.1	LUMEVOQ (lenadogene nolparvovec): GenSight Biologics
11.7	Retinitis Pigmentosa
11.7.1	CTx-PDE6b: Coave Therapeutics
11.7.2	Botaretigene sparoparvovec: Johnson & Johnson/ MeiraGTx
11.7.3	ATGC-501 (laruparetigene zosaparvovec): Applied Genetic Technologies Corporation
11.7.4	GS030: GenSight Biologics
11.7.5	MCO-010 (sonpiretigene isteparvovec): Nanoscope Therapeutics
11.7.6	4D-125: 4D Molecular Therapeutics
11.7.7	OCU400: Ocugen
11.7.8	jCell: jCyte
11.7.9	Human Retinal Progenitor Cells (hRPC): ReNeuron
11.8	Hunter Syndrome
11.8.1	RGX-121: REGENXBIO
11.9	Batten Disease
11.9.1	AT-GTX-502 (scAAV9.P546.CLN3): Amicus Therapeutics
11.1	Duchenne Muscular Dystrophy (DMD)
11.10.1	PF-06939926: Pfizer
11.10.2	SRP-9001: Sarepta Therapeutics
11.10.3	CAP-1002: Capricor Therapeutics/Nippon Shinyaku
11.11	Amyotrophic Lateral Sclerosis (ALS)
11.11.1	NurOwn (MSC-NTF cells): Brainstorm Cell Therapeutics
11.12	Beta Thalassemia and Sickle Cell Anemia
11.12.1	Exagamglogene autotemcel: CRISPR Therapeutics/Vertex Pharmaceuticals
11.12.2	EDIT-301: Editas Medicine
11.12.3	BIVV003: Sangamo Therapeutics
11.13	Dystrophic Epidermolysis Bullosa
11.13.1	VYJUVEK (beremagene geperpavec): Krystal Biotech
11.13.2	EB-101: Abeona Therapeutics
11.13.3	D-Fi (dabocemagene autoficel): Castle Creek Biosciences
11.13.4	RV-LAMB3-transduced epidermal stem cells: Holostem Terapie Avanzate S.r.l.
11.13.5	Allogenic ABCB5-positive Stem Cells: RHEACELL
11.13.6	ISN001: Ishin Pharma
11.13.7	ALLO-ASC-SHEET: Anterogen
11.14	Ornithine transcarbamylase deficiency (OTC Deficiency)
11.14.1	DTX301: Ultragenyx Pharmaceutical
11.15	Sanfilippo syndrome type A (MPS IIIA)
11.15.1	UX111 (ABO-102): Ultragenyx Pharmaceutical
11.16	Glycogen Storage disease Type IA
11.16.1	DTX401 (AAV8G6PC): Ultragenyx Pharmaceutical
12	Cell and Gene Therapies in Rare Disorders: 7MM analysis
12.1	Key Findings
12.2	Market Outlook
12.3	Conjoint Analysis
12.4	Key Market Forecast Assumptions
12.5	Indication-wise Market size of Cell and Gene Therapies in Rare Disorders in the 7MM
12.6	Market Size of Cell and Gene Therapies in Rare Disorders by Therapies in the 7MM
12.7	United States Market Size
12.8	EU4 and the UK Market Size
12.9	Japan Market Size
13	Unmet Needs
14	SWOT Analysis
15	KOL Views
16	Market Access and Reimbursement
17	Appendix
18	DelveInsight Capabilities
19	Disclaimer
20	About DelveInsight

Gene and Cell Therapies in Rare Disorder Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted gene and cell therapies in rare disorder epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Cell And Gene Therapy For Multiple Myeloma Market

Cell And Gene Therapy For Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cell and gene therapy for multiple myeloma companies, including Pfizer, MorphoSys, Biokine Therapeutics, Arcellx, Rapa Therapeutics, among others.

Gene Therapy For Ocular Rare Disease Pipeline

Gene Therapy For Ocular Rare Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key gene therapy for ocular rare disease companies, including Roche Holding, Novartis, Ocugen, among others.

Adeno-Associated Virus Vectors in Gene Therapy Market

Adeno-Associated Virus Vectors in Gene Therapy Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key adeno-associated virus vectors in gene therapy companies, including Pfizer, CSL Behring, Spark Therapeutics, Freeline Therapeutics, RegenxBio, Amicus Therapeutics, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP